Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121283 | 0.85 | AGTR1 (0.42) | AGTR1LTB4R2HDAC1HDAC6 | |
| SCHEMBL2118 | 0.84 | AGTR1 (0.55) | AGTR1LTB4R2ABCB11GP6HDAC1 | |
| SCHEMBL2382 | 0.84 | AGTR1 (0.60) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2381 | 0.84 | AGTR1 (0.60) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL2789 | 0.83 | AGTR1 (0.55) | AGTR1LTB4R2ABCB11GP6HDAC1 | |
| SCHEMBL10033 | 0.83 | AGTR1 (0.70) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL3138 | 0.83 | AGTR1 (0.55) | AGTR1LTB4R2ABCB11GP6 | |
| SCHEMBL1511 | 0.83 | AGTR1 (0.75) | AGTR1LTB4R2ABCB11GP6HDAC1 | |
| SCHEMBL1512 | 0.83 | AGTR1 (0.75) | AGTR1LTB4R2ABCB11GP6HDAC1 | |
| SCHEMBL2969136 | 0.83 | AGTR1 (0.58) | AGTR1LTB4R2ABCB11GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR1 8/4885LTB4R2 254/4885ABCB11 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.